<DOC>
	<DOC>NCT01332435</DOC>
	<brief_summary>This retrospective study aims to assess the economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI and alpha-blocker (AB) combination therapy. Both the Integrated Health Care Information Solutions and PharMetrics databases will be utilized for this study (2000-2007).</brief_summary>
	<brief_title>Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Male patients aged 50 years or older a medical claim of EP a prescription claim for a 5ARI and AB (provided both are within 180 days of index date) continuously eligible for 6 months prior to and at least 12 months after index prescription date. diagnosis of prostate or bladder cancer any prostaterelated surgical procedure within 5 months of index date prescription claim for finasteride indicative of male pattern baldness 5ARI therapy initiated prior to initiating AB therapy</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, early, costs</keyword>
</DOC>